Cargando…
FOXO1 Inhibition Yields Functional Insulin-Producing Cells In Human Gut Organoid Cultures
Generation of surrogate sources of insulin-producing β-cells remains a goal of diabetes therapy. While most efforts have been directed at differentiating embryonic or induced pluripotent stem (iPS) cells into β-like-cells through endodermal progenitors, we have shown that gut endocrine progenitor ce...
Autores principales: | Bouchi, Ryotaro, Foo, Kylie S., Hua, Haiqing, Tsuchiya, Kyoichiro, Ohmura, Yoshiaki, Sandoval, P. Rodrigo, Ratner, Lloyd E., Egl, Dieter, Leibel, Rudolph L., Accili, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083475/ https://www.ncbi.nlm.nih.gov/pubmed/24979718 http://dx.doi.org/10.1038/ncomms5242 |
Ejemplares similares
-
A Mutant Allele Encoding DNA Binding–Deficient FoxO1 Differentially Regulates Hepatic Glucose and Lipid Metabolism
por: Cook, Joshua R., et al.
Publicado: (2015) -
Liver Sinusoidal Endothelial Cells Link Hyperinsulinemia to Hepatic Insulin Resistance
por: Tsuchiya, Kyoichiro, et al.
Publicado: (2013) -
FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice
por: Lee, Yun-Kyoung, et al.
Publicado: (2021) -
Single-agent FOXO1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice
por: Lee, Yun-Kyoung, et al.
Publicado: (2022) -
Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes
por: Kitamoto, Takumi, et al.
Publicado: (2022)